CymaBay Therapeutics Reaches Analyst Target Price
February 13, 2024 at 12:33 PM EST
In recent trading, shares of CymaBay Therapeutics Inc (CBAY) have crossed above the average analyst 12-month target price of $28.45, changing hands for $32.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..